Curated News
By: NewsRamp Editorial Staff
May 04, 2026

NeuroOne Regains Nasdaq Compliance After Reverse Stock Split

Discuss on Substack Discuss on Telegram View History of this news story on GitHub
Original Source

TLDR

  • NeuroOne regained Nasdaq compliance via a 1-for-6 reverse stock split, boosting its stock's bid price above $1.
  • NeuroOne executed a reverse stock split to meet Nasdaq's minimum bid price, resolving its non-compliance after an extension.
  • NeuroOne's electrode technology aims to reduce surgeries and improve outcomes for patients with neurological disorders.
  • The company's electrode platform includes FDA-cleared products for brain and trigeminal nerve ablation procedures.

Impact - Why it Matters

This news matters because it ensures NeuroOne continues to be publicly traded on Nasdaq, providing liquidity and access to capital markets for investors. The company's FDA-cleared electrode and ablation technologies are critical for patients with neurological disorders, offering less invasive surgical options that can reduce hospitalizations and improve outcomes. Maintaining listing compliance supports ongoing R&D for future treatments in drug delivery and spinal cord stimulation, potentially benefiting a broader patient population.

Summary

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) has successfully regained compliance with Nasdaq's Minimum Bid Price Requirement, closing a previous deficiency notice. The company, a medical technology firm focused on neurological disorders, executed a 1-for-6 reverse stock split effective April 15, 2026, which brought its stock price above the $1 minimum threshold. The Nasdaq Listing Qualifications Department confirmed compliance on May 4, 2026, ending the matter that began with a deficiency notice in May 2025 and a subsequent 180-day extension granted in November 2025.

NeuroOne markets a portfolio of FDA-cleared products, including the Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These technologies are designed to improve surgical outcomes for neurological disorders by offering high-definition electrode precision and minimally invasive diagnostic and therapeutic options. The company is also advancing research in drug delivery, basivertebral nerve ablation, and spinal cord stimulation. For more details, visit nmtc1.com.

The reverse stock split, which adjusted shares at a 1-for-6 ratio, took effect at 5:00 p.m. ET on April 15, 2026, with trading on a split-adjusted basis beginning April 16. The stock continues under the symbol NMTC but now carries a new CUSIP number. This development underscores NeuroOne's commitment to maintaining its Nasdaq listing and advancing its mission to transform neurological surgical care. The NEWMEDIAWIRE release highlights the company's proactive steps to address listing requirements while continuing its innovative work in medical technology.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, NeuroOne Regains Nasdaq Compliance After Reverse Stock Split

blockchain registration record for this content.